Invesaro

Stocks Comparison

BioCorRx vs Concentra Group Holdings Parent: revenue, profit, margins and growth compared

BioCorRx brought in $797.2K of revenue in fiscal 2025, Concentra Group Holdings Parent $2.2B in fiscal 2025. Revenue changed by +10,301.1% at BioCorRx and +13.9% at Concentra Group Holdings Parent on the year before, so BioCorRx grew faster. BioCorRx kept -431.5% of its revenue as net profit, Concentra Group Holdings Parent 7.7%.

Side by side, latest fiscal year

BICXCON
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$797.2K$2.2B
Revenue growth+10,301.1%+13.9%
Net income-$3.4M$166.4M
Net margin-431.5%7.7%
Free cash flown/a$197.1M
Free cash flow marginn/a9.1%
Earnings per share (diluted)-$0.19$1.30
Cash$139.4K$79.9M
Debtn/a$1.6B
Price to earningsn/a27.2
Market value$6M$4.5B
Dividend yieldn/a0.71%
Rank by revenue in sector#655 of 742 · Health care#111 of 742 · Health care

Over the years

Revenue
BICX FY2018: $376.7KBICX FY2019: $240.3KBICX FY2020: $122.6KBICX FY2021: $48.3KBICX FY2022: $213.8KBICX FY2023: $89.2KBICX FY2024: $7.7KBICX FY2025: $797.2KCON FY2022: $1.7BCON FY2024: $1.8BCON FY2024: $1.9BCON FY2025: $2.2BFY18FY19FY20FY21FY22FY23FY24FY25
BICX $797.2KCON $2.2B
Net income
BICX FY2018: -$6.6MBICX FY2019: -$6MBICX FY2020: -$3.5MBICX FY2021: -$5.2MBICX FY2022: -$4.4MBICX FY2023: -$3.8MBICX FY2024: -$5.1MBICX FY2025: -$3.4MCON FY2022: $166.7MCON FY2024: $179.9MCON FY2024: $166.5MCON FY2025: $166.4MFY18FY19FY20FY21FY22FY23FY24FY25
BICX -$3.4MCON $166.4M
Net margin
BICX FY2018: -1,748.1%BICX FY2019: -2,517.4%BICX FY2020: -2,859.6%BICX FY2021: -10,794.3%BICX FY2022: -2,046.8%BICX FY2023: -4,228.9%BICX FY2024: -66,616.1%BICX FY2025: -431.5%CON FY2022: 9.7%CON FY2024: 9.8%CON FY2024: 8.8%CON FY2025: 7.7%FY18FY19FY20FY21FY22FY23FY24FY25
BICX -431.5%CON 7.7%
Revenue growth
BICX FY2019: -36.2%BICX FY2020: -49.0%BICX FY2021: -60.6%BICX FY2022: +343.0%BICX FY2023: -58.3%BICX FY2024: -91.4%BICX FY2025: +10,301.1%CON FY2024: +6.6%CON FY2024: +3.4%CON FY2025: +13.9%FY19FY20FY21FY22FY23FY24FY25
BICX +10,301.1%CON +13.9%
Free cash flow
BICX FY2018: -$1.8MBICX FY2019: -$2.8MBICX FY2020: -$2.2MBICX FY2021: -$3.5MBICX FY2022: -$2MCON FY2022: $228.4MCON FY2024: $169.4MCON FY2024: $210.4MCON FY2025: $197.1MFY18FY19FY20FY21FY22FY24FY25
BICX -$2MCON $197.1M

Fiscal years as each company reports them; the two may end in different months.

Questions about BioCorRx and Concentra Group Holdings Parent

Which is bigger by revenue, BioCorRx or Concentra Group Holdings Parent?

Concentra Group Holdings Parent is bigger by revenue: $2.2B in fiscal 2025, against $797.2K for BioCorRx in fiscal 2025.

Which keeps more of its revenue as profit, BioCorRx or Concentra Group Holdings Parent?

BioCorRx had a net margin of -431.5% in fiscal 2025; Concentra Group Holdings Parent had 7.7% in fiscal 2025.

Which grew revenue faster, BioCorRx or Concentra Group Holdings Parent?

In their latest fiscal years revenue changed by +10,301.1% at BioCorRx and +13.9% at Concentra Group Holdings Parent.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies